SU1232124A3 - Способ получени липоарабиноманнана,обладающего противоопухолевой активностью - Google Patents
Способ получени липоарабиноманнана,обладающего противоопухолевой активностью Download PDFInfo
- Publication number
- SU1232124A3 SU1232124A3 SU802943651A SU2943651A SU1232124A3 SU 1232124 A3 SU1232124 A3 SU 1232124A3 SU 802943651 A SU802943651 A SU 802943651A SU 2943651 A SU2943651 A SU 2943651A SU 1232124 A3 SU1232124 A3 SU 1232124A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- methyl
- lipoarabinomannan
- lipopolysaccharide
- producing
- possessing
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002028 Biomass Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 abstract description 11
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- GUSANBRNBREBPL-TZTIVRRBSA-N alpha-D-Ara-(1->5)-alpha-D-Ara-(1->3)-[alpha-D-Ara-(1->5)]-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->2)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)-[alpha-D-Man-(1->2)]-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-alpha-D-Man Chemical compound OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@H]3[C@H](O)[C@@H](OC[C@H]4O[C@H](OC[C@H]5O[C@H](O[C@H]6[C@@H](O)[C@H](O)[C@@H](CO[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)O[C@@H]6OC[C@H]6O[C@H](OC[C@H]7O[C@H](OC[C@H]8O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H](O)[C@@H]7O)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)O[C@@H]3CO[C@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GUSANBRNBREBPL-TZTIVRRBSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 4
- ZAZKJZBWRNNLDS-UHFFFAOYSA-N methyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC ZAZKJZBWRNNLDS-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 229920000057 Mannan Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HUEBIMLTDXKIPR-UHFFFAOYSA-N methyl heptadecanoate Chemical compound CCCCCCCCCCCCCCCCC(=O)OC HUEBIMLTDXKIPR-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- NGEZPLCPKXKLQQ-VOTSOKGWSA-N (e)-4-(3-methoxyphenyl)but-3-en-2-one Chemical compound COC1=CC=CC(\C=C\C(C)=O)=C1 NGEZPLCPKXKLQQ-VOTSOKGWSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8468179A JPS568320A (en) | 1979-07-04 | 1979-07-04 | Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1232124A3 true SU1232124A3 (ru) | 1986-05-15 |
Family
ID=13837428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU802943651A SU1232124A3 (ru) | 1979-07-04 | 1980-07-03 | Способ получени липоарабиноманнана,обладающего противоопухолевой активностью |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US4329452A (enExample) |
| JP (1) | JPS568320A (enExample) |
| CA (1) | CA1132047A (enExample) |
| CH (1) | CH650799A5 (enExample) |
| ES (1) | ES493061A0 (enExample) |
| FR (1) | FR2484258A1 (enExample) |
| IT (1) | IT1132168B (enExample) |
| SU (1) | SU1232124A3 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5718619A (en) * | 1980-07-10 | 1982-01-30 | Chisato Maruyama | Tumor immunotherapy agent containing lipopolysaccharide as active principle |
| JPS59161320A (ja) * | 1983-03-04 | 1984-09-12 | Maruyama Chisato | リポ多糖体およびその製造法 |
| US4612304A (en) * | 1985-06-11 | 1986-09-16 | Ss Pharmaceutical Co., Ltd. | Antitumor formulation containing lipopolysaccharide with trehalose derivatives |
| US4818751A (en) * | 1985-07-02 | 1989-04-04 | Zeria Shinyaku Kogyo Kabushiki Kaisha | Cosmetics |
| DK316188A (da) * | 1987-06-15 | 1988-12-16 | Duphar Int Res | Sulfolipopolysaccharider som stimolatorer for den ikke specifikke forsvarsmekanisme |
| US4798369A (en) * | 1987-11-03 | 1989-01-17 | The Firestone Tire & Rubber Company | Ultrasonic air spring system |
| US5853737A (en) * | 1992-12-10 | 1998-12-29 | Brigham And Women's Hospital | Method for inducing a CD1-restricted immune response |
| US6238676B1 (en) * | 1992-12-10 | 2001-05-29 | Brigham And Women's Hospital | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| US7063844B2 (en) | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| CA2160082C (en) * | 1994-10-07 | 1998-11-10 | Melvin E. Klegerman | Mixture having antitumor activities |
| US6274356B1 (en) * | 1997-06-10 | 2001-08-14 | Tai-Ho Chung | Carbohydrate complex extracted from Mycobacterium tuberculosis and process for the preparation thereof |
| US5869645A (en) * | 1997-10-15 | 1999-02-09 | Board Of Trustees Of The University Of Illinois | Method for isolating high molecular weight antineoplastic glycans using urea |
| NZ505538A (en) * | 2000-07-03 | 2004-12-24 | Malaghan Inst Of Medical Res | A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma |
| US8034359B2 (en) | 2004-06-07 | 2011-10-11 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
| NZ581806A (en) | 2004-06-07 | 2011-10-28 | Qu Biolog Inc | Bacterial compositions for the treatment of cancer |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US20070161546A1 (en) * | 2005-12-15 | 2007-07-12 | Colm King | Methods and compositions for treatment of cancer |
| US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
| JP2015157763A (ja) * | 2012-05-28 | 2015-09-03 | エヌエーアイ株式会社 | 認知症の治療剤及び予防剤 |
| AU2015241071A1 (en) | 2014-03-31 | 2016-10-27 | University Of Utah Research Foundation | Fluid analysis device and associated systems and methods |
| CA2947631A1 (en) | 2014-05-02 | 2015-11-05 | Qu Biologics Inc. | Anti-microbial immunomodulation |
| KR20230084177A (ko) * | 2020-10-09 | 2023-06-12 | 제리아 신야쿠 고교 가부시키 가이샤 | 결핵균 추출물의 신규 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1188519A (en) * | 1966-10-27 | 1970-04-15 | Wellcome Found | Method for the Purification of Lipopolysaccharides |
| FR2227862A1 (en) * | 1973-05-04 | 1974-11-29 | Anvar | Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues |
| NL7308450A (enExample) * | 1972-06-20 | 1973-12-27 | ||
| DE2527636A1 (de) * | 1974-06-20 | 1976-01-08 | Anvar | Verfahren zur herstellung von mycobakteriellen fraktionen |
-
1979
- 1979-07-04 JP JP8468179A patent/JPS568320A/ja active Granted
-
1980
- 1980-05-06 US US06/147,127 patent/US4329452A/en not_active Expired - Lifetime
- 1980-06-09 FR FR8012794A patent/FR2484258A1/fr active Granted
- 1980-07-03 ES ES493061A patent/ES493061A0/es active Granted
- 1980-07-03 CA CA355,290A patent/CA1132047A/en not_active Expired
- 1980-07-03 SU SU802943651A patent/SU1232124A3/ru active
- 1980-07-03 IT IT23219/80A patent/IT1132168B/it active
- 1980-07-03 CH CH5128/80A patent/CH650799A5/de not_active IP Right Cessation
-
1981
- 1981-08-18 US US06/293,999 patent/US4394502A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| За вка JP № 48-43842, сер.6(1), № сб. 46(46), 1973. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES8105783A1 (es) | 1981-06-16 |
| US4329452A (en) | 1982-05-11 |
| FR2484258A1 (fr) | 1981-12-18 |
| IT8023219A0 (it) | 1980-07-03 |
| JPS568320A (en) | 1981-01-28 |
| CA1132047A (en) | 1982-09-21 |
| JPS6256843B2 (enExample) | 1987-11-27 |
| CH650799A5 (de) | 1985-08-15 |
| FR2484258B1 (enExample) | 1984-11-30 |
| ES493061A0 (es) | 1981-06-16 |
| IT1132168B (it) | 1986-06-25 |
| US4394502A (en) | 1983-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1232124A3 (ru) | Способ получени липоарабиноманнана,обладающего противоопухолевой активностью | |
| Gottschalk | The chemistry and biology of sialic acids and related substances | |
| KR860000274B1 (ko) | 갱글리오사이드의 분자내 에스테르 유도체의 제조방법 | |
| US4395405A (en) | Alkyl-ketohexopyranoside derivatives and method of use | |
| JPH0657721B2 (ja) | 医薬および食品添加物として有用な、特に植物から抽出された多糖類 | |
| JPS6210240B2 (enExample) | ||
| JPH01157995A (ja) | 鎮痛−抗炎症活性を有するガングリオシドの内部エステル | |
| JPS6019719A (ja) | 抗腫瘍活性を有する蛋白質 | |
| Liav et al. | A new synthesis of cord factors and analogs | |
| SU1326197A3 (ru) | Способ получени N-ацетилмурамилпептидов | |
| US4067963A (en) | Substance acting to prevent and improve cerebral function disorder and process for preparing the same | |
| Philpot et al. | Lipids of living and killed tubercle bacilli | |
| JPH0133119B2 (enExample) | ||
| Pinckard et al. | Acetyl glyceryl ether phosphorylcholine: Platelet-activating factor | |
| US3002887A (en) | Method of purifying a dialyzable lipid mobilizer contained in blood | |
| EP0874851B1 (en) | Macrocyclic compounds made from carbon suboxide units | |
| RU2028303C1 (ru) | ПОЛИСАХАРИД ГАММА-ПЛАНТ (γ-PL), ОБЛАДАЮЩИЙ ПРОТИВОИНФЕКЦИОННЫМ ДЕЙСТВИЕМ И НЕ ОБЛАДАЮЩИЙ ГЕММАГЛЮТИНИРУЮЩИМ ДЕЙСТВИЕМ | |
| JP2013532759A (ja) | 虚血再灌流傷害の治療のための糖脂質 | |
| JPH09104693A (ja) | グリコシド類、グリコシドの無糖分解産物およびその誘導体 | |
| EP0134247A1 (en) | Protein with oncostatic effect, process for its preparation, and oncostatic drug containing it | |
| Hakomori et al. | Fractionation of compound lipids by dialysation in an organic solvent against an organic solvent | |
| CA1169433A (en) | Method for preparing an antihypertensive agent comprising 1-0-alkyl-2-acetoyl-sn-glycero-3- phosphocholine | |
| JPS60181019A (ja) | ガングリオシドの抽出方法 | |
| JPS6361959B2 (enExample) | ||
| US2695862A (en) | Process for obtaining vitamin b12 |